Summary The effect of intraperitoneal (i.p.) injection of recombinant human interleukin-lp (rhIL-1p) was studied in three i.p. nude mouse xenograft models of human ovarian cancer (HU, OS, and LA). Intraperitoneal rhIL-lp administration led to a dose dependent replacement of peritoneal ascitic tumour with solid tumours attached to the peritoneum and intraabdominal viscera in two (HU and LA) out of the three xenograft models. In the third xenograft model (OS), low doses of rhIL-p (10 ng day) promoted micrometastatic peritoneal implants of tumour, but higher doses of rhIL-Ip (1 fig day) Interleukin-I (IL-1) and tumour necrosis factor (TNF) are pleiotropic cytokines with overlapping biological activities (Le & Vilcek, 1987; Dinarello, 1991) . TNF has been extensively studied in experimental murine tumour models and in human cancer xenograft models (Palladino et al., 1987; Asher et al., 1987; Haranaka et al., 1984; Balkwill et al., 1986) . IL-1 has growth inhibitory effects on several human tumour cell lines in vitro (Tsai & Gaffney, 1986; Ruggiero & Baglioni, 1987; Onozaki et al., 1985) , and antitumour effects in murine tumour models (Braunschweiger et al., 1988; Nakamura et al., 1986; Berladelli et al., 1989 ), but has not been extensively studied in human cancer xenograft models. Although TNF has been shown to induce IL-1 in a variety of cell types in vitro (Philip & Epstein, 1986; Elias et al., 1989) , and in vivo (Dinarello et al., 1986), there have been no reported studies assessing the contribution of TNF-induced IL-1 to the effect of TNF in experimental animal models to date.
Interleukin-I (IL-1) and tumour necrosis factor (TNF) are pleiotropic cytokines with overlapping biological activities (Le & Vilcek, 1987; Dinarello, 1991) . TNF has been extensively studied in experimental murine tumour models and in human cancer xenograft models (Palladino et al., 1987; Asher et al., 1987; Haranaka et al., 1984; Balkwill et al., 1986) . IL-1 has growth inhibitory effects on several human tumour cell lines in vitro (Tsai & Gaffney, 1986; Ruggiero & Baglioni, 1987; Onozaki et al., 1985) , and antitumour effects in murine tumour models (Braunschweiger et al., 1988; Nakamura et al., 1986; Berladelli et al., 1989 ), but has not been extensively studied in human cancer xenograft models. Although TNF has been shown to induce IL-1 in a variety of cell types in vitro (Philip & Epstein, 1986; Elias et al., 1989) , and in vivo (Dinarello et al., 1986) , there have been no reported studies assessing the contribution of TNF-induced IL-1 to the effect of TNF in experimental animal models to date.
In studies of the effects of rhTNF in intraperitoneal human ovarian cancer xenograft models, i.p.rhTNF therapy prolonged the survival of mice bearing two of three human ovarian cancer xenografts, but also enhanced the peritoneal implantation of tumour cells . Other studies suggested that TNF production by human ovarian cancers may contribute to the biological behaviour of these tumours in man (Malik et al., 1990; Naylor et al., 1990) . production by tumours may also contribute to tumour pathophysiology, for example by inducing hypercalcaemia (Sato et al., 1987) and promoting growth, adhesion and metastasis of tumour cells (Giavazzi et al., 1990; Bani et al., 1991; Gelin et al., 1991) . The studies reported in this paper show that IL-1, like TNF, can have pronounced antitumour activity, but can also enhance the implantation of human ovarian cancer cells in the peritoneal cavity. Although the effects of TNF and IL-1 on tumour implantation were similar, there was a notable difference in the susceptibility of the ovarian cancer xenografts to the antitumour effect of the cytokines.
Materials and methods
Xenografts and mice Six to 12 week old specific pathogen free female nu/nu (nude) mice of mixed genetic background were maintained as described previously (Balkwill et al., 1982) . Ovarian cancer xenografts OS, LA, and HU were established from primary human tumours as described previously (Ward et al., 1987 were labelled with 32P-dCTP by random priming (Feinberg & Vogelstein, 1984) . Membranes were hybridised to the labelled probes using a standard method (Church & Gilbert, 1984) . After high stringency washing, the membranes were exposed to film (Kodak XAR5) for up to 7 days at -70°C. Probes TNF, PstI fragment of p-hTNF 1 (Prof. W. Fiers, University of Gent, Gent, Belgium): IL-la and IL-1p, pSPhIL-la.2 and pSPhL-1p.2 (Dr. Alan Shaw, Glaxo Institute for Molecular Biology, Geneva, Switzerland).
Biological assay for interleukin-J
The assay used was as described by Gearing et al. (1987) , and is based on the IL-1 induced release of IL-2 from a murine thymocyte cell line (NOB-1). The amount of IL-2 released is assayed by measuring the IL-2 stimulated 3H-thymidine uptake in an IL-2-dependent murine T cell line (CTLL). The NOB-1 cells were grown in RPMI/5% FCS and the CTLL cells in RPMI/10% FCS with 10 U/recombinant IL-2 (37°C, 5% CO2). Both cell lines were passaged every 2-3 days, by splitting the total number of cells 1:10. For assay of IL-1 activity in the peritoneal cavity after injection of rhTNF, three mice were killed by CO2 inhalation at various time points after the injection of 1 ,ug rhTNF. The peritoneal cavity was lavaged with cold RPMI, the lavage fluid centrifuged (1,500 r.p.m. for 5 min), and the supernatants collected. The IL-1 activity of lavage fluid was assessed by incubating 100 IlA with NOB cells (5 x I04 in 100 til) for 24 h (37C, 5% C02) in microtiter plates (Costar). rhIL-1p therapy led to marked improvement of survival (P <0.005), whereas rhTNF did not have any significant effects. Dose response studies in the OS xenograft model showed that daily i.p. injections of rhIL-l,B at doses as low as 1 ng also significantly prolonged their survival compared to diluent treated mice. In a typical experiment, 65% of mice treated with 1 ng rhIL-l,/day were alive at 100 days, whereas all the diluent treated mice had died with ascitic tumour by 25 days.
Effects of IL-1lp and rhTNF on peritoneal cell populations The comparative effects of rhTNF and rhIL-lp on PMN influx were studied in the three xenograft models, 24 h after a single injection of cytokines (Figure 2 ). The following conclusions could be drawn from the data: (a) rhTNF and IL-1p significantly (P<0.05 to P<0.01) increased the total PEC count in the three xenograft models compared to diluent injected mice.
(b) Intraperitoneal injection of rhIL-lp led to a significantly greater increase in the number of PECs at 24 h than that induced by rhTNF in the OS and LA (but not HU) bearing mice (P <0.05 and <0.005 respectively).
(c) The proportion of PMNs in rhIL-lp treated mice was significantly greater than that in rhTNF treated mice (P< 0.005, <0.025, and <0.025 for the OS, HU and LA bearing mice respectively).
(d) The total number of PMNs in rhIL-lp treated mice was significantly greater than that in rhTNF treated mice (P <0.005; <0.025 and <0.025 for the OS, HU and LA bearing mice respectively).
(e) The increase in absolute numbers of PEC at 24 h was solely due to an increase in the numbers of PMN. 3H-thymidine incorporation were noted after 24 h of culture. After 72 h, no effects were seen in the HU xenograft in vitro (data not shown). 3H-thymidine incorporation by the LA xenograft was not affected by rhIL-l,, but was significantly inhibited (P <0.005) at concentrations of rhTNF greater than lOngml1l (Figure 3a) . In contrast, rhTNF did not inhibit 3H-thymidine incorporation by OS tumour cells, but rhIL-1l3 markedly inhibited 3H-thymidine incorporation at concentrations as low as 100 pg ml-' (Figure 3b ).
Histological and post-mortem studies Post-mortem studies in HU and LA bearing mice treated with diluent revealed free floating ascitic tumours at all times from tumour injection to death (Figure 4a) . However, i.p.
rhIL-1p injection led to marked macroscopic solid tumour implantation in the peritoneal cavity in the HU and LA xenograft models, with eradication of ascitic tumour. Histological examination revealed implantation of islands of viable tumour cells in a well formed stromal reaction (Figure 4b ) that stained for collagen, laminin, and fibronectin. In OS mice treated with 1 jig day i.p. rhIL-1P, there was no macroscopic evidence of tumour implantation or ascitic tumour. Peritoneal lavage fluid cytospin preparations from mice treated with rhTNF 7 days after commencement of therapy, revealed viable tumour cells in rhTNF treated mice (Figure 4c ), whilst the tumour cells seen in the lavage fluid of rhIL-lp treated mice showed marked degenerative changes as early as 3 days after commencement of therapy (Figure 4d ).
However, the presence of viable ascitic tumour was noted in some mice that were treated with low dose of rhIL-l,B
(1-1Ongday) up to 20 days after start of therapy. At postmortem, microscopic peritoneal and diaphragmatic deposits of tumour were seen in these mice (Figure 4e ). Some mice treated with doses of 10 ng day had survived up to 100 days without outward signs of tumour, but at post mortem, although there was no ascitic tumour, tumour implants were visible in the peritoneal cavity. In one experiment, of the five mice that were surviving with no outward signs of tumour up to 100 days after treatment with 10 ng day rhIL-1,, four mice had microscopic deposits of tumour on the diaphragms, and two of these mice also had macroscopically visible deposits of tumour on the uterus and ovaries (Figure 4f ). These tumours were well encapsulated, and occasionally showed areas of dystrophic calcification. As with the other two xenografts, control mice always showed ascitic tumour at post mortem. There was no evidence of solid tumour deposits.
IL-I induction by rhTNF
The release of IL-1 bioactivity in peritoneal lavage fluid with time in OS tumour bearing mice after injection of I Ag rhTNF was assessed ( Figure 5) . A significant increase in IL-1 bioactivity was detected in peritoneal lavage fluid 60 min after rhTNF injection, with peak activity at 90 min. The peak level of activity corresponded to a concentration of 70 pg ml-' of rhIL-1,. The IL-1 bioactivity declined thereafter, but was still significantly higher at 24 h compared to baseline values. No significant rise in IL-1 activity was noted after the injection of rhTNF in non-tumour bearing mice. The IL-1 activity in peritoneal washes was not neutralised by antihuman IL-1 antibodies, but was neutralised by antimurine IL-1 antibody (data not shown). (Figure 3a) .
The potential role of TNF induced IL-1 release in the HU and LA xenograft models was studied by assessing tumour implantation after 7 days of therapy. There was no evidence of tumour implantation in any of the mice treated with i.p. injection of rhIL-ll lower than lOOngday, suggesting that physiological levels of IL-1 released after TNF injection did not contribute to the TNF induced tumour implantation.
Conversely, there was no evidence that rhIL-lp led to the induction of TNF mRNA in the human ovarian cancer xenografts, or that injection of rhTNF at doses less than lOOngday led to tumour implantation ( Figure 6 ).
Discussion
This study has analysed the effects and interrelationships of i.p. administration of rhIL-lp and rhTNF in three intraperitoneal human ovarian cancer xenograft models. RhIL-lp was shown to cause peritoneal implantation and solid tumour formation in two out of the three xenograft models (HU and LA) at doses of 1 ig day. In a third xenograft model (OS), rhIL-lp had a marked antitumour effect by acting directly on the tumour cells. Although IL-1 has been shown to inhibit the growth of ovarian cancer cell lines in vitro (Killian et al., 1991) Although PMNs have been implicated in the antitumour effects of TNF and other i.p. therapies (Lichtenstein et al., 1989; Shau, 1988) , differences in peritoneal PMN influx could not account for the differential effects of these cytokines in the present study. In vitro studies showed that the marked antitumour effect of rhIL-lp was due to a direct effect on OS tumour cells. The differential cytotoxicity of TNF and rhIL1p for OS tumour cells are under investigation.
The mechanisms underlying the promotion of tumour implantation by rhIL-lp and TNF in these models are likely to be complex in view of the multiple cell regulatory effects of these cytokines. Histological analysis of peritoneal implants showed that there was marked generation of tumour stroma which may enhance tumour implantation. TNF and IL-1 have both been shown to have effects on fibroblast proliferation and the generation of stroma (Kovacs, 1990) . A preliminary step to this may be the induction of increased adhesion of tumour cells to the peritoneal mesothelium. Studies in this laboratory have shown that TNF increased the adhesion of the ovarian cancer xenografts to peritoneal explants in vitro (Malik, 1991) , and it is likely that IL-1 will have similar effects on tumour adhesion as suggested by other investigators (Giavazzi et al., 1990; Bani et al., 1991) . There was a notable difference in the effects of rhTNF and rhIL-lp on tumour implantation in the HU xenograft model. RhIL-lp consistently led to the formation of a greater solid tumour burden than that seen in TNF treated mice. This may indicate an additional growth promoting effect of rhIL-lp on this tumour xenograft in vivo.
TNF has been shown to induce IL-1 in several cell populations, e.g. monocytes, endothelial cells and fibroblasts (Philip & Epstein, 1986; Elias et al., 1989) . The present study demonstrated that TNF induced IL-1 release from the murine host, but not the human tumour cells. The most probable cellular source of IL-1 in tumour bearing mice is likely to be the peritoneal macrophage population. We were unable to detect significant levels of IL-1 in peritoneal lavage fluid from non-tumour bearing mice. Previous studies have shown that the injection of the human ovarian cancer xenografts leads to a marked increase in the peritoneal macrophage population. However, although IL-1 release was readily detectable in tumour bearing mice following injection of rhTNF, similar doses of rhIL-1 did not reproduce the effects of TNF in the HU and LA models. The low levels of IL-1 released may have however contributed to tumour implantation in the OS xenograft model.
There is increasing evidence of dysregulated cytokine biology in human ovarian cancer (Malik & Balkwill, 1991) . Previous studies have implicated endogenous TNF produc-E cm Os tion in the pathophysiology of human ovarian cancer Malik et al., 1990; Naylor et al., 1990; Takeyama et al., 1991; Dejaco et al., 1991) . Some ovarian cancers have been noted to express IL-1p mRNA and protein (unpublished data), and this cytokine may also contribute to the peritoneal spread of human ovarian cancer. However, it is also possible that IL-1 may have significant antitumour activity against some ovarian cancers, and the present study indicates that it may be possible to identify these by testing the sensitivity of these tumours to IL-1 in vitro.
